Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + pemetrexed as second-line treatment for recurrent or metastatic cervical cancer
ChiCTR1900027815Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and pemetrexed in Cervical Cancer (CC), sponsored by Union Hospital. Primary endpoints: Objective response rate, Disease control rate and 1 more. Started Nov 2019; status: recruiting.
02
Drugs
sintilimabpemetrexed
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900027815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027815.